Instrument NameRoche Holdings Ltd ADRInstrument Symbol(RHHBY)

Instrument ExchangeOTC US

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Morningstar recently ranked the 10 most undervalued stocks to buy in October. I found three unusually active options that stood out as attractive bets on these struggling stocks.

Telemedicine once seemed like it was going to revolutionize healthcare.

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

The company had a dispiriting update to offer about an investigational drug.

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines...

The urgent need for innovative technologies to accelerate the development of life-saving cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential to shorten drug development timelines is paramount. DNA-damage response (DDR)-based therapies, which target cancer cells' repair mechanisms, are emerging...

Should Novo Nordisk and Eli Lilly investors be worried about Roche?

There are a number of pharmaceutical companies looking to make waves in the weight loss market.

/CNW/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates. Johns...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – Pancreatic cancer is among the deadliest cancers, prompting...

News from a competitor gave investors an unwelcome dose of reality.

The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth.

/CNW/ -- USA News Group – How and what we eat is always changing. But for more and more people, the options to eat are drastically being reduced, due to rising...

Roche's latest breakthrough could be a game changer, but it's still too early to say.

Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category.

Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.

This company hasn't made its debut on the weight-loss market yet, but it may.

Neither is a leader right now, but one of them might be on track to change that.

Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the reintroduction of Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people in the United States (U.S.)...

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita increases in the incidence of leading...